Who are Sulfamethoxazole Trimethoprim Combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sulfamethoxazole-Trimethoprim, Sulfadoxine-pyrimethamine used for IPTi.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sulfamethoxazole-trimethoprim-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sulfamethoxazole Trimethoprim Combination — Competitive Intelligence Brief

Sulfamethoxazole Trimethoprim Combination (Sulfamethoxazole Trimethoprim Combination) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide-dihydrofolate reductase inhibitor combination. Area: Infectious Disease.

marketed Sulfonamide-dihydrofolate reductase inhibitor combination Dihydropteroate synthase; Dihydrofolate reductase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Sulfamethoxazole Trimethoprim Combination (Sulfamethoxazole Trimethoprim Combination) — Baylor Research Institute. Sulfamethoxazole-trimethoprim is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydropteroate synthase and dihydrofolate reductase, respectively.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Sulfamethoxazole Trimethoprim Combination TARGET	Sulfamethoxazole Trimethoprim Combination	Baylor Research Institute	marketed	Sulfonamide-dihydrofolate reductase inhibitor combination	Dihydropteroate synthase; Dihydrofolate reductase
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole-Trimethoprim	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Sulfonamide-dihydrofolate reductase inhibitor combination	Dihydropteroate synthase; Dihydrofolate reductase
Sulfadoxine-pyrimethamine used for IPTi	Sulfadoxine-pyrimethamine used for IPTi	Swiss Tropical & Public Health Institute	phase 3	Antifolate antimalarial combination	Dihydropteroate synthase; Dihydrofolate reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide-dihydrofolate reductase inhibitor combination class)

Baylor Research Institute · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sulfamethoxazole Trimethoprim Combination — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfamethoxazole-trimethoprim-combination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab